Ecabet

Ecabet sodium (TA-2711) is currently applied to some clinical gastrointestinal disease by inhibiting the ROS production and improving Helicobacter pylori eradication[1]. Ecabet sodium reduces apoptosis[2]

Product Specifications

CAS Number

[33159-27-2]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Bacterial; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ecabet.html

Solubility

10 mM in DMSO

Smiles

O=C([C@]1(C)CCC[C@]2(C)C3=C(CC[C@@]12[H])C=C(C(C)C)C(S(=O)(O)=O)=C3)O

Molecular Formula

C20H28O5S

Molecular Weight

380.50

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Wang Y, et al. Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. Helicobacter. 2014 Oct;19 (5) :372-81.|[2]Rah YC, et al. Ecabet sodium alleviates neomycin-induced hair cell damage. Free Radic Biol Med. 2015 Dec;89:1176-83.